Medpace Holdings Inc
MEDP: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| qT< | LOCK|cHs> | LOCK|$QZjdH# |
Medpace Earnings: Stock Soars 55% on Significantly Higher Backlog Conversion and Fewer Cancellations
Medpace's second-quarter revenue increased 14% from the prior year, and its backlog conversion rate was 21%. Management increased its 2025 revenue guidance by 13% at the midpoint and raised its net income guidance by nearly 7%. Shares soared 55% on the better-than-expected results.
